Latest Breaking News On - Difference in patient - Page 1 : comparemela.com

This month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS) that’s administered through the nose.

Tanuja chitnisGabriele cerroneProfessor of neurology at harvard medical schoolTiziana lifeSecondary progressive multiple sclerosisHave few effective treatment optionsHave even fewerDifference in patientEmission tomographyModified fatigue impact scalePrincipal investigatorHarvard medical schoolExpanded disability status scaleFoot walk testNeuroqol fatigueTiziana founder gabriele